Human IFN-γ T cell ELISPOT antibody pair - 10-plate

SKU
CT640-10
Validated ELISPOT antibody pair; reagents available separately (960 determinations).
Format
10-plate
Price
€ 655
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ
Description
Our ELISPOT antibody pairs are validated for high assay performance using the same reagents and materials included in U-CyTech ELISPOT kits. These antibody pairs are optimized for reliable and reproducible ELISPOT assays.
The antibody pairs are available in convenient 10-plate and 20-plate format, providing 960 or 1920 determinations, respectively.
Compatible reagents for ELISPOT assays can be purchased separately, allowing customization of your ELISPOT workflow.
Description
IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor responses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.
Alternative names
IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon
Image

References

Authors, et al. Title Journal Year Volume Pages
Astrid van Halteren A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease Blood 2023 141 1277-1292
Lu Li Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants Front Cell Infect Microbiol 2023 13 1277880
Dong Wei Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination Emerg Microbes Infect 2022 11 2474-2484
Kevin Flanigan A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2 Mol Ther Methods Clin Dev 2022 27 47-60
Sui Peng Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma Cancer Immunol Res 2022 10 728-744
Aleixandra Rojas High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes Ther Drug Monit 2022 44 369-376
Elena Pancisi Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center Vaccines (Basel) 2022 10 999
Yuk-Fun Liu Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes Diabetes 2022 71 722-732
Soledad Henriquez Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma Blood 2022 139 942-946
Zhaotao Li Impaired T-Lymphocyte Responses During Childhood Staphylococcus aureus Infection J Infect Dis 2022 225 177-185